1 study found for:    23602668 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants
Conditions: Respiratory Syncytial Virus (RSV);   Parainfluenza Virus Type 3 (PIV3)
Interventions: Biological: MEDI-534;   Biological: Placebo

Indicates status has not been verified in more than two years